Sign In
Buy DSNKY
$15.23
-0.94 (-5.81%)
At Close: Jun 03, 2026
Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript
08:23am, Friday, 01'st Aug 2025
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 FY2025 Earnings Call July 31, 2025 4:30 AM ET Company Participants Asakura - VP of Corporate Communications Koji Ogawa - Senior Executive Officer and C
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
DSNKY vs. ZTS: Which Stock Is the Better Value Option?
12:46pm, Wednesday, 04'th Jun 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY) and Zoetis (ZTS).
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
05:00pm, Thursday, 22'nd May 2025
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American S
TAK or DSNKY: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 02'nd May 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Approaching the business with a 'patient-centric mindset': Daiichi Sankyo CEO
12:43am, Monday, 28'th Apr 2025
Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S. tarif
Daiichi Sankyo Company, Limited (DSKYF) FY2024 Earnings Call Transcript
12:43am, Saturday, 26'th Apr 2025
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) FY2024 Earnings Conference Call April 25, 2025 2:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Hiroyuki Okuzawa - Represe
TAK vs. DSNKY: Which Stock Is the Better Value Option?
12:46pm, Wednesday, 16'th Apr 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
12:45pm, Monday, 31'st Mar 2025
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
TAK or DSNKY: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 14'th Mar 2025
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
TAK vs. DSNKY: Which Stock Is the Better Value Option?
12:46pm, Monday, 17'th Feb 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Incoming Daiichi Sankyo CEO shares business roadmap going forward
02:30am, Monday, 03'rd Feb 2025
Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with AstraZene
Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript
10:21pm, Friday, 31'st Jan 2025
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q3 2024 Earnings Call Transcript January 31, 2025 1:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Koji Ogawa -
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
11:05pm, Thursday, 30'th Jan 2025
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. M
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
11:00am, Monday, 13'th Jan 2025
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumo
